Home What is Buprenorphine? Buprenorphine Products DATA Physician Locator DATA 2000 FAQs Notices Links En Español
Physician Waiver Qualifications Waiver Notification Form Upcoming Trainings Waived Physician WebBoard Update Physician Contact Information Model State Medical Board Policy
Buprenorphine Summits Articles SAMHSA Reports Other Gov't Reports
Nurses Guide to Buprenorphine
The Drug Addiction Treatment Act of 2000 (DATA 2000)The Drug Addiction Treatment Act of 2000 (DATA 2000) expands the clinical context of medication-assisted opioid addiction treatment by allowing qualified physicians to dispense or prescribe specifically approved Schedule III, IV, and V narcotic medications for the treatment of opioid addiction in treatment settings other than the traditional Opioid Treatment Program (i.e., methadone clinic). In addition, DATA 2000 reduces the regulatory burden on physicians who choose to practice opioid addiction therapy by permitting qualified physicians to apply for and receive waivers of the special registration requirements defined in the Controlled Substances Act. more
American Association for the Treatment of Opioid Dependence (AATOD) 2013 ConferenceThe City of Philadelphia, its Department of Behavioral Health Intellectual Disability Services, the State of Pennsylvania and its Department of Drug and Alcohol Programs are proud to host the American Association for the Treatment of Opioid Dependence (AATOD) 2013 Conference. Please visit the AATOD 2013 Conference Page for additional information on the exciting opportunities in addiction treatment being offered at this conference.
Get Your Copy of the Opioid Overdose ToolkitThe Opioid Overdose Toolkit educates first responders, physicians, patients, family members, and community members on ways to prevent opioid overdose. The toolkit also explains how to use a drug called naloxone to prevent overdose-related deaths. For additional information on the toolkit, please click here. To download your free copy, please visit the SAMHSA Store.
CSAT Director Announces Upcoming Release of a New FDA Approved Buprenorphine ProductOn July 3, 2013, Orexo U.S. Inc. became the latest pharmaceutical company to add to the ever growing list of buprenorphine products. Orexo received approval from the U.S. Food and Drug Administration (FDA) for Zubsolv (buprenorphine and naloxone) sublingual tablets. Zubsolv is indicated for the maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Zubsolv is due to be released in September 2013. Click here to read the letter in its entirety.
A Recent Study Looking at the Treatment Outcomes Versus Type of Treatment Medication UsedThe authors of this study seek to explore differences in baseline clinical characteristics and opioid replacement therapy treatment outcomes by type or combined and route (injector or non-injector) of opioid use. Click here to read the study in its entirety.
CSAT Director Discusses Fentanyl AnaloguesMany of you will remember the period from 2005 through 2007 when illicit fentanyl-laced heroin caused a great number of overdose deaths. That was not the first time illicit fentanyl, also called fentanyl analogues, entered the drug market, and likely will not be the last. Recently, small clusters of overdoses and overdose fatalities in a variety of communities, mostly in the eastern United States, have raised alarm. Little is yet fully known about the situation but it appears fentanyl analogues are involved in at least some of the cases and may contaminate both heroin and cocaine. Click here to read the letter in its entirety.
What's New Help with RSS
Treatment Improvement Protocol
Increase Patient Limits
2005 SAMHSA Evaluation of the Impact of the DATA Waiver Program
2006 Report On Diversion and Abuse of Buprenorphine
Drug Enforcement Administraton (DEA)
DATA Physician Locator
CSAT Director Informs Physicians of Increase in Patient Limits
CSAT Director Notifies Physicians of a New Feature to the SAMHSA Buprenorphine Physician and Treatment Program Locator
CSAT Director Advises Physicians of Concerns Regarding Buprenorphine
CSAT Director Encouraging Physicians to Sign-Up for the Buprenorphine Physician and Treatment Program Locator
Home | Accessibility | Privacy | Disclaimer | SAMHSA
Department of Health & Human Services | USA.gov
* Adobe™ PDF formatted files require the Adobe™ Reader to properly read them. Use this link to download this FREE program.